Proteasomal Degradation of Mcl-1 by Maritoclax Induces Apoptosis and Enhances the Efficacy of ABT-737 in Melanoma Cells
暂无分享,去创建一个
Krishne Gowda | S. Amin | Hong-Gang Wang | M. Pandey | Arun K. Sharma | Hong-Gang Wang | Kenichiro Doi | Manoj K. Pandey | Kenichiro Doi | Shantu Amin | K. Gowda
[1] P. Insel,et al. Increased Expression of the Pro-apoptotic Protein BIM, a Mechanism for cAMP/Protein Kinase A (PKA)-induced Apoptosis of Immature T Cells* , 2011, The Journal of Biological Chemistry.
[2] Yan Liu,et al. Discovery of Marinopyrrole A (Maritoclax) as a Selective Mcl-1 Antagonist that Overcomes ABT-737 Resistance by Binding to and Targeting Mcl-1 for Proteasomal Degradation* , 2012, The Journal of Biological Chemistry.
[3] P. Hersey,et al. Modulation of NOXA and MCL-1 as a Strategy for Sensitizing Melanoma Cells to the BH3-Mimetic ABT-737 , 2011, Clinical Cancer Research.
[4] Gang Li,et al. The role of Bcl-2 family members in the progression of cutaneous melanoma , 2004, Clinical & Experimental Metastasis.
[5] C. Rudin,et al. A Phase II Study of AT-101 (Gossypol) in Chemotherapy-Sensitive Recurrent Extensive-Stage Small Cell Lung Cancer , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[6] P. Hersey,et al. Up-regulation of Mcl-1 is critical for survival of human melanoma cells upon endoplasmic reticulum stress. , 2008, Cancer research.
[7] Ahmedin Jemal,et al. Cancer Statistics, 2002 , 2002, CA: a cancer journal for clinicians.
[8] Andreas Villunger,et al. Bmf: A Proapoptotic BH3-Only Protein Regulated by Interaction with the Myosin V Actin Motor Complex, Activated by Anoikis , 2001, Science.
[9] J. Eberle,et al. Expression and Function of Bcl-2 Proteins in Melanoma , 2008, Current genomics.
[10] S. Korsmeyer,et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours , 2005, Nature.
[11] S. Cory,et al. Killing cancer cells by flipping the Bcl-2/Bax switch. , 2005, Cancer cell.
[12] H. Xin,et al. Enhanced killing of melanoma cells by simultaneously targeting Mcl-1 and NOXA. , 2006, Cancer research.
[13] R. Bataille,et al. Melphalan-induced apoptosis in multiple myeloma cells is associated with a cleavage of Mcl-1 and Bim and a decrease in the Mcl-1/Bim complex , 2005, Oncogene.
[14] Stefano Volinia,et al. miR-181b is a biomarker of disease progression in chronic lymphocytic leukemia. , 2011, Blood.
[15] Yihong Ma,et al. Flavopiridol-induced apoptosis is mediated through up-regulation of E2F1 and repression of Mcl-1. , 2003, Molecular cancer therapeutics.
[16] G. Cohen,et al. Bcl-2 inhibitors: small molecules with a big impact on cancer therapy , 2009, Cell Death and Differentiation.
[17] Xingming Deng,et al. Cleavage of Bax to p 18 Bax accelerates stress-induced apoptosis , and a cathepsin-like protease may rapidly degrade p 18 Bax , 2003 .
[18] D. L. Wilburn,et al. Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer. , 2008, Cancer research.
[19] G. Gao,et al. N‐terminal cleavage of Bax by calpain generates a potent proapoptotic 18‐kDa fragment that promotes Bcl‐2‐independent cytochrome C release and apoptotic cell death , 2000, Journal of cellular biochemistry.
[20] Lin Chen,et al. Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. , 2005, Genes & development.
[21] Q. Yao,et al. Mesothelin confers pancreatic cancer cell resistance to TNF-α-induced apoptosis through Akt/PI3K/NF-κB activation and IL-6/Mcl-1 overexpression , 2011, Molecular Cancer.
[22] Erinna F. Lee,et al. Structural insights into the degradation of Mcl-1 induced by BH3 domains , 2007, Proceedings of the National Academy of Sciences.
[23] S. Fesik,et al. ‘Seed’ analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737 , 2007, Oncogene.
[24] John Calvin Reed,et al. Sabutoclax, a Mcl-1 antagonist, inhibits tumorigenesis in transgenic mouse and human xenograft models of prostate cancer. , 2012, Neoplasia.
[25] P. Dent,et al. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. , 2007, Cancer research.
[26] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[27] K. Lei,et al. JNK phosphorylation of Bim-related members of the Bcl2 family induces Bax-dependent apoptosis , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[28] M. Amiot,et al. Noxa controls Mule-dependent Mcl-1 ubiquitination through the regulation of the Mcl-1/USP9X interaction. , 2011, Biochemical and biophysical research communications.
[29] M. Hung,et al. Down-regulation of myeloid cell leukemia-1 through inhibiting Erk/Pin 1 pathway by sorafenib facilitates chemosensitization in breast cancer. , 2008, Cancer research.
[30] Laurent Bélec,et al. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis , 2007, Proceedings of the National Academy of Sciences.
[31] Derek W. Yecies,et al. Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. , 2010, Blood.
[32] V. Sondak,et al. Targeting mutant BRAF and KIT in metastatic melanoma: ASCO 2009 meeting report , 2009, Pigment Cell & Melanoma Research.
[33] Rodney J Hicks,et al. In Vivo Activity of Combined PI3K/mTOR and MEK Inhibition in a KrasG12D;Pten Deletion Mouse Model of Ovarian Cancer , 2011, Molecular Cancer Therapeutics.
[34] D. Altieri,et al. Drug Resistance in Melanoma: Mechanisms, Apoptosis, and New Potential Therapeutic Targets , 2004, Cancer and Metastasis Reviews.
[35] C. Ploner,et al. Endogenous Noxa Determines the Strong Proapoptotic Synergism of the BH3-Mimetic ABT-737 with Chemotherapeutic Agents in Human Melanoma Cells. , 2009, Translational oncology.
[36] R. Jove,et al. 6-Bromoindirubin-3'-oxime inhibits JAK/STAT3 signaling and induces apoptosis of human melanoma cells. , 2011, Cancer research.
[37] J. Gu,et al. ABT-737 Induces Bim Expression via JNK Signaling Pathway and Its Effect on the Radiation Sensitivity of HeLa Cells , 2012, PloS one.
[38] Thomas S. Lin,et al. Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab. , 2009, Blood.
[39] J. Opferman,et al. A competitive stapled peptide screen identifies a selective small molecule that overcomes MCL-1-dependent leukemia cell survival. , 2012, Chemistry & biology.
[40] H. Pehamberger,et al. Mcl-1 antisense therapy chemosensitizes human melanoma in a SCID mouse xenotransplantation model. , 2003, The Journal of investigative dermatology.
[41] S. Lowe,et al. Apoptosis and melanoma chemoresistance , 2003, Oncogene.
[42] A. Perets,et al. Enhancing the vascularization of three-dimensional porous alginate scaffolds by incorporating controlled release basic fibroblast growth factor microspheres. , 2003, Journal of biomedical materials research. Part A.
[43] A. Villunger,et al. Bim and Bmf in tissue homeostasis and malignant disease , 2008, Oncogene.
[44] Brian A. Chauder,et al. Discovery of potent myeloid cell leukemia 1 (Mcl-1) inhibitors using fragment-based methods and structure-based design. , 2013, Journal of medicinal chemistry.
[45] V. Tron,et al. RNA Silencing of Mcl-1 Enhances ABT-737-Mediated Apoptosis in Melanoma: Role for a Caspase-8-Dependent Pathway , 2009, PloS one.
[46] J. Eberle,et al. Loss of proapoptotic Bcl-2-related multidomain proteins in primary melanomas is associated with poor prognosis. , 2006, The Journal of investigative dermatology.
[47] Qiang Liu,et al. Anti-cancer drug discovery and development , 2012, Communicative & integrative biology.
[48] R. Craig,et al. MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[49] John Calvin Reed,et al. Bax cleavage is mediated by calpain during drug-induced apoptosis , 1998, Oncogene.
[50] C. Scott,et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. , 2006, Cancer cell.
[51] S. Huh,et al. Melanoma Chemoprevention in Skin Reconstructs and Mouse Xenografts Using Isoselenocyanate-4 , 2010, Cancer Prevention Research.
[52] C. Antonescu,et al. KIT as a therapeutic target in metastatic melanoma. , 2011, JAMA.
[53] B. Aggarwal,et al. Gambogic acid, a novel ligand for transferrin receptor, potentiates TNF-induced apoptosis through modulation of the nuclear factor-kappaB signaling pathway. , 2007, Blood.
[54] W. May,et al. Cleavage of Bax to p18 Bax accelerates stress-induced apoptosis, and a cathepsin-like protease may rapidly degrade p18 Bax. , 2003, Blood.
[55] H. Pehamberger,et al. Expression of Bcl-2 family members in human melanocytes, in melanoma metastases and in melanoma cell lines , 1998, Melanoma research.
[56] H. Yamaguchi,et al. Anoikis, initiated by Mcl-1 degradation and Bim induction, is deregulated during oncogenesis. , 2007, Cancer research.
[57] Ceri M. Wiggins,et al. Apoptosis and autophagy: BIM as a mediator of tumour cell death in response to oncogene‐targeted therapeutics , 2009, The FEBS journal.
[58] N. Hayashi,et al. The Bcl‐xL inhibitor, ABT‐737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib , 2010, Hepatology.
[59] H. Pehamberger,et al. Chemosensitisation of malignant melanoma by BCL2 antisense therapy , 2000, The Lancet.
[60] P. Fisher,et al. Targeting Mcl-1 for the therapy of cancer , 2011, Expert opinion on investigational drugs.
[61] Anupama Munshi,et al. Clonogenic cell survival assay. , 2005, Methods in molecular medicine.
[62] P. Dorrestein,et al. Marinopyrrole A target elucidation by acyl dye transfer. , 2009, Journal of the American Chemical Society.
[63] Apurva R. Patel,et al. AlgiMatrix™ Based 3D Cell Culture System as an In-Vitro Tumor Model for Anticancer Studies , 2013, PloS one.